Avalo Therapeutics Inc. (AVTX)
NASDAQ · Healthcare
Avalo Therapeutics Inc. Operating Income 2015–2025
Avalo Therapeutics Inc. annual/quarterly operating income history and growth rate from 2015 to 2025. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.
- Avalo Therapeutics Inc. operating income for the quarter ending September 30, 2025 was -19.2 M, a 49.27% increase year-over-year.
- Avalo Therapeutics Inc. operating income for the twelve months ending September 30, 2025 was -74.4 M, a 377.02% increase year-over-year.
- Avalo Therapeutics Inc. annual operating income for 2025 was -72.9 M, a 6.44% increase from 2024.
- Avalo Therapeutics Inc. annual operating income for 2024 was -68.5 M, a 150.49% increase from 2023.
- Avalo Therapeutics Inc. annual operating income for 2023 was -27.4 M, a 26.95% decrease from 2022.
- Avalo Therapeutics Inc. annual operating income for 2022 was -37.4 M.
Operating Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Avalo Therapeutics Inc. Operating Income — FAQ
Avalo Therapeutics Inc. (AVTX) operating income over the last 11 years — annual and quarterly figures with year-over-year growth and charts.
What is Avalo Therapeutics Inc.'s operating income?
Avalo Therapeutics Inc. (AVTX) reported operating income of -$73M for fiscal 2025.
Where can I see AVTX's operating income history?
The chart and table above show Avalo Therapeutics Inc.'s operating income by year and by quarter, including the growth rate.